This segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Ascentage Pharma's R&D activities include the development of small molecule inhibitors targeting key cancer pathways. Technologies employed include drug discovery platforms, clinical trial design, and biomarker identification. The therapeutic areas covered include leukemia, lymphoma, and solid tumors. The patient impact is significant, aiming to improve survival rates and quality of life for cancer patients. Ascentage Pharma's market positioning is strengthened by its focus on unmet medical needs and its collaborations with other pharmaceutical companies. Future opportunities include expanding the pipeline and entering new markets. Regulatory and clinical aspects involve rigorous clinical trials and seeking regulatory approvals. Partnerships and collaborations are crucial for advancing the development and commercialization of its products.

This segment concentrates on developing therapies for age-related diseases, including those related to HBV. Research and development efforts involve identifying and validating drug targets, designing and synthesizing drug candidates, and conducting preclinical and clinical studies. The company utilizes various technologies, including medicinal chemistry, pharmacology, and clinical trial management. Therapeutic areas include chronic HBV infection. The patient impact is aimed at improving the health and well-being of individuals affected by age-related diseases. Ascentage Pharma aims to establish a strong market position by addressing unmet medical needs and leveraging its scientific expertise. Future opportunities include expanding the pipeline and exploring new therapeutic areas. Regulatory and clinical aspects involve navigating the regulatory approval process and conducting clinical trials. Partnerships and collaborations are essential for advancing research and development.